Search clinical trials for: Hedgehog

Total 95 results

Anne Chang
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

Skin Basal Cell Carcinoma

United States
Medical University of Warsaw

Unknown

The Search for Viral and Bacterial Etiology of Varicocele (ViBaVa)

Bacterial Infections | Varicocele | Viral Infection | Sonic Hedgehog Expression | VEGF Expression

Poland
Jason K. Sicklick, M.D.
Novartis Pharmaceuticals

Completed

LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis

Hepatocellular Carcinoma | Cirrhosis

United States
National Cancer Institute (NCI)

Terminated

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

Prostate Adenocarcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
University of Miami

Terminated

Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients

Esophageal Cancer

United States
PellePharm, Inc.

Completed

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas (BCC)

Basal Cell Carcinomas

United States
Cubist Pharmaceuticals LLC

Terminated

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (RENSE)

Renal Impairment | Complicated Skin and Skin Structure Infections | S. Aureus Bacteremia

United States
National Cancer Institute (NCI)

Completed

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Recurrent Uterine Corpus Sarcoma | Chondrosarcoma | Recurrent Osteosarcoma | Gastrointestinal Stromal Tumor | Clear Cell Sarcoma of the Kidney | Metastatic Osteosarcoma | Ovarian Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult... and other conditions

United States
Stanford University
National Cancer Institute (NCI); University Hospitals Cleveland Medical Center

Completed

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

Recurrent Skin Cancer | Basal Cell Carcinoma of the Skin

United States
Clinica Universidad de Navarra, Universidad de...

Unknown

Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients (SHH-CM)

Breast Cancer

Spain
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)

Completed

Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer

Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer

United States
Genentech, Inc.

Completed

A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Solid Cancers
Genentech, Inc.

Completed

A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

Healthy
Genentech, Inc.

Completed

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Genentech, Inc.

Completed

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

Ovarian Cancer
National Cancer Institute (NCI)

Completed

Evaluation of Food Effect on Pharmacokinetics of Vismodegib

Malignant Neoplasm

United States
Novartis Pharmaceuticals

Withdrawn

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Basal Cell Carcinoma

Greece, Switzerland, Germany, United Kingdom, Belgium, Canada, Czechia, Finland, Italy, Spain
Novartis Pharmaceuticals

Completed

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Glioma | Astrocytoma | Medulloblastoma | Neuroblastoma | Rhabdomyosarcoma | Hepatoblastoma

France, Canada, Italy, Australia, United Kingdom, United States
Infinity Pharmaceuticals, Inc.

Completed

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States, Canada
Anne Chang
Novartis

Completed

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Basal Cell Carcinoma

United States
University of Utah

Withdrawn

A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma

Adult Medulloblastoma

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
National Cancer Institute (NCI)

Completed

Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Recurrent Childhood Medulloblastoma

United States
Erasme University Hospital
Ipsen; Fonds National de la Recherche Scientifique

Completed

Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure (Erasme-POF)

Lymphoma | Fertility Preservation | Alkylating Agents

Belgium, France, Italy
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Nevoid Basal Cell Carcinoma Syndrome | Basal Cell Carcinoma | Gorlin Syndrome

Belgium, Austria, Germany, Canada
Genentech, Inc.
National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center...

Completed

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Genentech, Inc.

Completed

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Solid Cancers

United States
Genentech, Inc.

Completed

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Basal Cell Carcinoma

Australia, France, United States, Germany, Belgium, United Kingdom
National Cancer Institute (NCI)

Terminated

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Genentech, Inc.

Completed

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Metastatic Colorectal Cancer | Ovarian Cancer | Basal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Novartis Pharmaceuticals; Rutgers Cancer Institute...

Withdrawn

A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer

Resectable Pancreatic Cancer

United States
Bristol-Myers Squibb
Exelixis

Completed

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Basal Cell Carcinoma (BCC) | Hedgehog Pathway | Smoothened | Basal Cell Nevoid Syndrome (BCNS)

United States, Canada
National Cancer Institute (NCI)

Completed

GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

Recurrent Childhood Medulloblastoma

United States
University of Colorado, Denver

Completed

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

Recurrent Head and Neck Cancer

United States
Lisa Bax
Roche Pharma AG; Genentech, Inc.

Terminated

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) (HIPPoS)

Pancreatic Ductal Adenocarcinoma

United Kingdom
Third Affiliated Hospital, Sun Yat-Sen University
National Natural Science Foundation of China

Unknown

Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis

Arthritis, Rheumatoid | Neovascularization, Pathologic | Synovitis
Infinity Pharmaceuticals, Inc.

Completed

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

Primary Myelofibrosis | Fibrosis, Bone Marrow

United States
Jean-Luc Van Laethem
Roche Pharma AG

Unknown

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer (NEOPACHI-001)

Pancreatic Adenocarcinoma Resectable

Belgium
Infinity Pharmaceuticals, Inc.

Completed

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Neoplasms

United States, Canada
Pfizer

Completed

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

Osteoarthritis

United States

Search clinical trials for: Hedgehog

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations